Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 2/20 | 0.33 |
| ▸ | LCK | P06239 | 2/20 | 0.32 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | KLK7 | P49862 | 1/20 | 0.30 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.30 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10201670 | 0.89 | FKBP1A (0.36) | CASP3ACELCKKMT2A | |
| SCHEMBL10248534 | 0.85 | ACE (0.41) | CASP3ACEAVPR2MEN1KMT2A | |
| SCHEMBL10201660 | 0.81 | CASP3 (0.39) | CASP3NPC1ACEAVPR2MEN1 | |
| SCHEMBL12443735 | 0.80 | CASP3 (0.39) | CASP3NPC1ACEAVPR2LMNA | |
| SCHEMBL1410178 | 0.78 | LCK (0.45) | CASP3ACELCK | |
| SCHEMBL1410179 | 0.78 | LCK (0.45) | CASP3ACELCK | |
| SCHEMBL11113427 | 0.76 | CASP3 (0.40) | CASP3NPC1ACEMEN1KMT2A | |
| SCHEMBL10671600 | 0.75 | ACE (0.41) | CASP3NPC1ACELCKROCK2 | |
| SCHEMBL644711 | 0.74 | ACE (0.40) | CASP3NPC1ACELCKROCK2 | |
| SCHEMBL949749 | 0.74 | ACE (0.40) | CASP3NPC1ACELCKROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-8119631-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | CASP3 85/4885NPC1 948/4885ACE 16/4885 |
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | CASP3 85/4885NPC1 948/4885ACE 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.